SOUTH SAN FRANCISCO, Calif., February 04, 2025--SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for Non-Opioid Pain Treatment ...

SiteOne’s STC-004 is an oral small molecule designed to target NaV1.8. In February, SiteOne reported Phase 1 results showing STC-004 was rapidly absorbed with a half-life that supports once ...

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain.

In February, SiteOne announced positive results from an early-stage study on STC-004, which showed that the drug was safe and well-tolerated at all dose levels while also improving pain tolerance.

SiteOne’s drug candidate, STC-004, is on track to begin Phase 2 testing. SiteOne develops drugs that target sodium channels, which are found primarily in the peripheral nervous system.

Like Vertex's Journavx (suzetrigine), cleared by the FDA in February for moderate-to-severe acute pain, STC-004 is an oral inhibitor of the NaV1.8 sodium channel, blocking a pain-signalling ...

The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain. STC-004 may represent a next-generation, non-opioid treatment for patients suffering ...

Notably, the mechanism utilized by STC-004 was validated earlier this year when the FDA approved Vertex Pharmaceuticals’ Journavx — also a Nav1.8 inhibitor — for treating adults with ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion. SiteOne, founded in 2010, is ...